Lurasidone – financial conflicts of interest

The launch in the UK of Lurisidone began in August 2014. My previous post on Lurasidone (Latuda) which has now been marketed in the UK followed the financial interests of … Continue reading Lurasidone – financial conflicts of interest

Stephen Stahl: $3,581,159 in payments from Pharma

In my last post I considered the level of transparency provided by the British Association for Psychopharmacology (BAP) in relation to its recently published Guidelines on prescribing for depressive disorders. … Continue reading Stephen Stahl: $3,581,159 in payments from Pharma

British Association for Psychopharmacology Guidelines (BAP)

The above Evidence-based guidelines for treating depressive disorders with antidepressants have recently been published. The British Association for Psychopharmacology are an organisation highly regarded by my profession of psychiatry. 12% of their … Continue reading British Association for Psychopharmacology Guidelines (BAP)